v3.26.3
Reportable Segment Information (Tables)
12 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Information About Domestic and International Operations

Information about Ashland’s domestic and international operations for the years ended September 30, are as follows. Ashland has no operations in any individual international country or single customer that represented more than 10% of sales during the years ended September 30, 2026, 2025 and 2024.

 

 

Sales to external
customers

 

 

Net assets
(liabilities)

 

 

Property, plant and
equipment - net

 

(In millions)

 

2026

 

 

2025

 

 

2024

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

United States

 

$

462

 

 

$

464

 

 

$

624

 

 

$

720

 

 

$

872

 

 

$

789

 

 

$

848

 

International

 

 

1,401

 

 

 

1,360

 

 

 

1,489

 

 

 

1,128

 

 

 

1,032

 

 

 

345

 

 

 

353

 

 

 

$

1,863

 

 

$

1,824

 

 

$

2,113

 

 

$

1,848

 

 

$

1,904

 

 

$

1,134

 

 

$

1,201

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Summary of Financial Information for Each Reportable Segment

The following table presents various financial information for each reportable segment for the years ended September 30:

 

(In millions)

 

2026

 

 

2025

 

 

2024

 

Sales

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

671

 

 

$

641

 

 

$

810

 

Personal Care

 

 

592

 

 

 

577

 

 

 

634

 

Specialty Additives

 

 

504

 

 

 

511

 

 

 

572

 

Intermediates

 

 

135

 

 

 

137

 

 

 

144

 

Intersegment sales(a)

 

 

(39

)

 

 

(42

)

 

 

(47

)

 

 

$

1,863

 

 

$

1,824

 

 

$

2,113

 

Cost of sales

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

411

 

 

$

418

 

 

$

515

 

Personal Care

 

 

350

 

 

 

345

 

 

 

398

 

Specialty Additives

 

 

423

 

 

 

433

 

 

 

522

 

Intermediates

 

 

117

 

 

 

121

 

 

 

107

 

Intersegment sales

 

 

(39

)

 

 

(42

)

 

 

(47

)

 

 

$

1,262

 

 

$

1,275

 

 

$

1,495

 

Selling, general and administrative expense

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

97

 

 

$

77

 

 

$

89

 

Personal Care

 

 

87

 

 

 

84

 

 

 

95

 

Specialty Additives

 

 

70

 

 

 

64

 

 

 

61

 

Intermediates

 

 

6

 

 

 

7

 

 

 

7

 

   Total operating segments

 

 

260

 

 

 

232

 

 

 

252

 

Unallocated and other

 

 

117

 

 

 

112

 

 

 

152

 

 

 

$

377

 

 

$

344

 

 

$

404

 

Research and development expense

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

14

 

 

$

15

 

 

$

15

 

Personal Care

 

 

23

 

 

 

25

 

 

 

26

 

Specialty Additives

 

 

14

 

 

 

12

 

 

 

11

 

Intermediates

 

 

—

 

 

 

—

 

 

 

—

 

   Total operating segments

 

 

51

 

 

 

52

 

 

 

52

 

Unallocated and other

 

 

4

 

 

 

2

 

 

 

3

 

 

 

$

55

 

 

$

54

 

 

$

55

 

Intangibles amortization expense

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

18

 

 

$

18

 

 

$

23

 

Personal Care

 

 

32

 

 

 

35

 

 

 

43

 

Specialty Additives

 

 

9

 

 

 

9

 

 

 

10

 

Intermediates

 

 

1

 

 

 

1

 

 

 

—

 

 

 

$

60

 

 

$

63

 

 

$

76

 

Equity and other income

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

—

 

 

$

—

 

 

$

—

 

Personal Care

 

 

1

 

 

 

1

 

 

 

—

 

Specialty Additives

 

 

—

 

 

 

—

 

 

 

—

 

Intermediates

 

 

—

 

 

 

—

 

 

 

—

 

   Total operating segments

 

 

1

 

 

 

1

 

 

 

—

 

Unallocated and other

 

 

3

 

 

 

3

 

 

 

6

 

 

 

$

4

 

 

$

4

 

 

$

6

 

 

 

 

 

 

 

 

 

 

 

 

 

(In millions)

 

2026

 

 

2025

 

 

2024

 

Goodwill impairment and loss on divestitures, net

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

—

 

 

$

375

 

 

$

—

 

Personal Care

 

 

—

 

 

 

—

 

 

 

—

 

Specialty Additives

 

 

—

 

 

 

331

 

 

 

—

 

Intermediates

 

 

—

 

 

 

—

 

 

 

—

 

   Total operating segments

 

 

—

 

 

 

706

 

 

 

—

 

Unallocated and other

 

 

8

 

 

 

161

 

 

 

115

 

 

 

$

8

 

 

$

867

 

 

$

115

 

Operating income (loss)

 

 

 

 

 

 

 

 

 

Life Sciences(b)

 

$

131

 

 

$

(262

)

 

$

168

 

Personal Care(c)

 

 

101

 

 

 

90

 

 

 

73

 

Specialty Additives(d)

 

 

(12

)

 

 

(338

)

 

 

(32

)

Intermediates

 

 

11

 

 

 

8

 

 

 

29

 

   Total operating segments

 

 

231

 

 

 

(502

)

 

 

238

 

Unallocated and other(e)

 

 

(126

)

 

 

(273

)

 

 

(264

)

   Total operating income (loss)

 

$

105

 

 

$

(775

)

 

$

(26

)

Net interest and other expense (income)

 

 

40

 

 

 

33

 

 

 

(24

)

Other net periodic benefit (income) loss

 

 

(4

)

 

 

1

 

 

 

22

 

Income (loss) from continuing operations before income taxes

 

$

69

 

 

$

(809

)

 

$

(24

)

 

 

 

 

 

 

 

 

 

 

EBITDA(f)

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

187

 

 

$

(187

)

 

$

229

 

Personal Care

 

 

161

 

 

 

155

 

 

 

152

 

Specialty Additives

 

 

51

 

 

 

(254

)

 

 

89

 

Intermediates

 

 

16

 

 

 

21

 

 

 

42

 

   Total operating segments

 

 

415

 

 

 

(265

)

 

 

512

 

Unallocated and other

 

 

(125

)

 

 

(273

)

 

 

(264

)

   Total EBITDA

 

$

290

 

 

$

(538

)

 

$

248

 

Depreciation expense

 

 

125

 

 

 

174

 

 

 

198

 

Amortization expense

 

 

60

 

 

 

63

 

 

 

76

 

Net interest and other expense (income)

 

 

40

 

 

 

33

 

 

 

(24

)

Other net periodic benefit (income) loss

 

 

(4

)

 

 

1

 

 

 

22

 

Income (loss) from continuing operations before income taxes

 

$

69

 

 

$

(809

)

 

$

(24

)

 

 

 

 

 

 

 

 

 

 

Depreciation expense

 

 

 

 

 

 

 

 

 

Life Sciences(g)

 

$

38

 

 

$

57

 

 

$

38

 

Personal Care(h)

 

 

28

 

 

 

30

 

 

 

36

 

Specialty Additives(i)

 

 

54

 

 

 

75

 

 

 

111

 

Intermediates

 

 

4

 

 

 

12

 

 

 

13

 

   Total operating segments

 

 

124

 

 

 

174

 

 

 

198

 

Unallocated and other(j)

 

 

1

 

 

 

—

 

 

 

—

 

 

 

$

125

 

 

$

174

 

 

$

198

 

 

 

 

 

 

 

 

 

 

 

 

(In millions)

 

2026

 

 

2025

 

 

2024

 

Additions to property, plant and equipment

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

31

 

 

$

49

 

 

$

61

 

Personal Care

 

 

9

 

 

 

7

 

 

 

11

 

Specialty Additives

 

 

42

 

 

 

34

 

 

 

61

 

Intermediates

 

 

4

 

 

 

3

 

 

 

2

 

Unallocated and other

 

 

2

 

 

 

5

 

 

 

2

 

 

 

$

88

 

 

$

98

 

 

$

137

 

 

 

 

 

 

 

 

 

 

 

 

(In millions)

 

2026

 

 

2025

 

Assets

 

 

 

 

 

 

Life Sciences

 

$

1,422

 

 

$

1,498

 

Personal Care

 

 

701

 

 

 

751

 

Specialty Additives

 

 

964

 

 

 

1,020

 

Intermediates

 

 

116

 

 

 

116

 

Unallocated and other

 

 

1,324

 

 

 

1,226

 

 

 

$

4,527

 

 

$

4,611

 

Property, plant and equipment - net

 

 

 

 

 

 

Life Sciences

 

$

440

 

 

$

481

 

Personal Care

 

 

106

 

 

 

101

 

Specialty Additives

 

 

463

 

 

 

484

 

Intermediates

 

 

31

 

 

 

30

 

Unallocated and other

 

 

94

 

 

 

105

 

 

 

$

1,134

 

 

$

1,201

 

 

 

 

 

 

 

 

(a)
Intersegment sales from Intermediates are accounted for at prices that approximate market value. All other intersegment sales are accounted for at cost.
(b)
Includes $16 million of capital projects impairment charges in 2026 and goodwill impairment of $375 million for Life Sciences in 2025.
(c)
Includes capital projects impairment charge of $11 million for Personal Care in 2024.
(d)
Includes $2 million of capital projects impairment charges in 2026 and goodwill impairment of $331 million for Specialty Additives in 2025.
(e)
Includes a $3 million gain on sale of excess corporate properties, a $2 million excess land contract termination fee income and a $13 million Argentina foreign currency cumulative translation adjustment in 2026, $8 million gain on sale and a $183 million impairment charge related to the divestiture of the Avoca business in 2025, and a $8 million loss on sale and a $99 million impairment charge related to the divestiture of the Nutraceuticals business in 2024 within the loss on divestitures, net.
(f)
Excludes loss from discontinued operations, net of income taxes and other net periodic benefit (income) loss. See the Statements of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.
(g)
Depreciation includes accelerated depreciation of $21 million for Life Sciences in 2025.
(h)
Depreciation includes accelerated depreciation of $1 million, $1 million and $2 million for Personal Care in 2026, 2025 and 2024, respectively.
(i)
Depreciation includes accelerated depreciation of $3 million, $19 million and $55 million for Specialty Additives in 2026, 2025 and 2024, respectively.
(j)
Depreciation includes accelerated depreciation of $1 million for Unallocated and other in 2026.